Humacyte Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
HUMA$0.59+29.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(in thousands except for share amounts)
| Common Stock · AdditionalPaid-in Capital · AccumulatedDeficit · Total Stockholders’Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance as of December 31, 2023 | 103,673,728 | $10 | $550,850 | $(537,314) | $13,546 |
| Issuance of stock in public offering, net of issuance costs | 15,410,000 | 2 | 43,044 | — | 43,046 |
| Proceeds from the exercise of stock options | 625 | — | 2 | — | 2 |
| Stock-based compensation | — | — | 1,454 | — | 1,454 |
| Net loss | — | — | — | (31,896) | (31,896) |
| Balance as of March 31, 2024 | 119,084,353 | $12 | $595,350 | $(569,210) | $26,152 |
| Common Stock · AdditionalPaid-in Capital · AccumulatedDeficit · Total Stockholders’Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance as of December 31, 2022 | 103,229,013 | $10 | $543,456 | $(426,538) | $116,928 |
| Proceeds from the exercise of stock options | 100,158 | — | 119 | — | 119 |
| Stock-based compensation | — | — | 1,809 | — | 1,809 |
| Net loss | — | — | — | (36,969) | (36,969) |
| Balance as of March 31, 2023 | 103,329,171 | $10 | $545,384 | $(463,507) | $81,887 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.